Last updated:
December 08, 2014
* Perinatal data are the Perinatal Data Page
** Pediatric data are in
the Pediatric Data Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
|
XX International AIDS Conference
|
|
XIX International AIDS Conference
|
-
POSTER
Scaling-up of triggered viral load in rural Zimbabwe: implications for
phasing out of D4T
S. Van Den Broucke, S. Simons, K. Kranzer, et al
Poster
Abstract
-
Body weight
evolution in HIV-positive patients over two years of antiretroviral
treatment: a multiregional analysis
of the IeDEA
collaboration
D. Huis in 't Veld, E. Balestre, J.
Menten, et al
Abstract
-
Lactate monitoring
in adult Malawians on stavudine
N. Chagoma, S. Kaunda, J. Mallewa
Abstract
-
The HIV NRTI
BMS-986001 does not degrade mitochondrial DNA in long term primary cultures of
cells isolated from human kidney, muscle and subcutaneous fat
F. Wang, O. Flint
Abstract
-
A WEEK-IN-REVIEW FEATURED
REPORT
POSTER
Toxicity associated with the decrease of stavudine dosage from 40mg to 30mg in
first-line antiretroviral therapy
M. Pujades-Rodriguez, E. Dantony, L. Pinoges, et al
Poster
Abstract
- POSTER
Reason for changing first line antiretroviral
treatment before and after the implementation of the 2006
WHO guidelines
B. Castelnuovo, A. Kiragga, J. Ssempa, Y. Manabe
Poster
Abstract
-
POSTER
Improvement of lipodystrophy in children after substitution of stavudine with
zidovudine in NNRTI-based antiretroviral
therapy
L. Aurpibul, T. Puthanakit, S. Taejaroenkul, et al
Poster
Abstract
-
Rapid implementation of
2010 World Health Organization (WHO) recommendation for phasing out use of
Stavudine-based highly active antiretroviral therapy (HAART) for adult
HIV-infected patients in Maputo, Mozambique
S. Kelbert, M. Machado Cavalca Vieira, M.B. Pedro Matsinhe
Abstract
-
Treatment-modifying
toxicity and mortality among HIV-positive patients in Botswana
M. Farahani, H. Bussmann, C.W. Wester, et al
Abstract
-
Sustainability of
stavudine-based ART: nine out of ten replace stavudine by six years of treatment
in Cambodia
C. Kimcheng, V. Phan, S. Thai, et al
Abstract
-
Evaluating different
strategies for transitioning patients from stavudine to tenofovir in
resource-constrained settings
P. Grant, A. Talbot, E. Bendavid, et al
Abstract
|
ZDV/3TC vs d4T/3TC Outcomes among HIV-1-infected
Adults Receiving First-line Combination ART
in Botswana: Results from a Clinical Trial
W Wester, M Blevins, H Bussmann, et al
PDF Poster
Abstract
Genome-wide
Changes in Subcutaneous Adipose Tissue Gene Expression in HIV-uninfected Adults
after
2 Weeks of
ZDV or d4T with 3TC
C
Satchell, P Doolan, J Mehta, et al
Abstract
NVP and
3TC-resistant HIV-1 Detected in Antiretroviral-naïve Kenyans Initiating
NNRTI-based ART
S Dross, M Chung, J Kiarie, et al
Abstract
XVIII International AIDS Conference
|
|
| |
Eight out of ten adults on
stavudine-based antiretroviral treatment develop treatment-limiting
lipodystrophy by six years of treatment in Cambodia
J. van Griensven, V. Phan, S. Thai, et al
PDF Poster
Abstract
POSTER
Weight loss after the first year of stavudine-containing antiretroviral therapy
and its key
determinants at primary health care level in Kigali, Rwanda
J. van Griensven1, R. Zachariah, R. Colebunders, T. Reid
PDF Poster
Abstract
POSTER
Realities of reduction of stavudine use by HIV caregivers in resource limited
settings
O. Adenusi, O. Adebiyi, A. Etsetowaghan, et al
PDF Poster
Abstract
Effects of a reduced
dose of stavudine (d4T) on the incidence and severity of peripheral
neuropathy in PLHIV in South Africa
M. Pahuja, M.J. Glesby, A. Grobler, et al
Abstract
|
-
POSTER
Stavudine toxicity
in women is the main reason for treatment change in a 3 year prospective cohort
of adult patients started on first line antiretroviral treatment (ART) in
Uganda
B. Castelnuovo, A. Kiragga, M. Kamya, et al
PDF Poster
Abstract
-
Incidence of
peripheral neuropathy among patients receiving HAART regimens containing
stavudine
vs. zidovudine in Kenya
J. Njoroge, W. Reidy, G. John-Stewart.
et al
Abstract
-
Toxicity to fixed
dose stavudine, lamivudine and nevirapine in Uganda is very high but not
associated with increased virologic failure
F.C. Semitala, A. Kasirye-Kiragga, B. Castelnuovo, et al
Abstract
-
Long term
virological and immunological outcomes after stavudine-related lactic acidosis
in rural
KwaZulu-Natal
C. Houlihan, P.C. Mutevedz, R. Lessells, et al
Abstract
XVII International AIDS Conference
|
-
Weight evolution in patients after stavudine substitution for lipoatrophy in
Rwanda: comparison of zidovudine with tenofovir/abacavir
J. van Griensven, F. Rasschaert, E.F. Atté
POSTER -
Changes in Body Composition
Attributable to Lamivudine, Stavudine, Zidovudine, and Abacavir in HIV-infected
Persons Initiating ART
J Shlay, S Sharma, G Bartsch,, et al
PDF Poster
Abstract
-
Outcome
of Stavudine-induced Peripheral Neuropathy in HIV-infected Individuals in Rural
Uganda
G Mwima, D Moore, W Were, et
al
-
POSTER
Nevirapine Pharmacokinetics in Thai
Children Receiving either an Adult or Pediatric Fixed-dose
Combination of Stavudine, Lamivudine, and Nevirapine
K Chokephaibulkit, T Cressey, W Prasitsuebsai, et al
PDF Poster
Abstract
-
Adverse Effect of ddI, ddC and d4T as a Component of HAART on
Cognitive Function
during HIV Infection
I Husstedt, B
Hudelmeier, U Oelker-Gruneberg, et al
Abstract
|
Stavudine
Main Page
